Literature DB >> 31559181

Hereditary breast cancer: screening and risk reducing surgery.

Matteo Renzulli1, Simone Zanotti2, Alfredo Clemente3, Giangaspare Mineo4, Francesco Tovoli5, Alfonso Reginelli3, Antonio Barile6, Salvatore Cappabianca3, Mario Taffurelli2, Rita Golfieri1.   

Abstract

BACKGROUND: The screening modalities for women at high risk for breast cancer has received an increasing role during the last years. The aim of this study was to evaluate the performance of our screening program comparing the diagnostic sensitivity of clinical breast examination, mammography, ultrasonography (US) and magnetic resonance imaging (MRI).
METHODS: Clinical Breast examination, mammography, US and MRI for each patient with BRCA1 and BRCA2 mutation who underwent breast surgery in our Institution from October 2008 to April 2016 were retrospectively evaluated. The diagnostic accuracy for MRI and for the other surveillance tests in identifying early breast cancer were assessed.
RESULTS: Twenty-six female patients with genetic mutation underwent breast surgery. Twenty-two out of 26 (85%) developed cancer during the dedicated screening protocol whereas 4 women who underwent surgery did not have cancer. Imaging was able to detect cancer in all 22 patients (per patient sensibility of 100%), identifying all 35 neoplastic lesions (per lesion sensibility of 100%). The combination of Clinical Breast Examination, US and mammography aided the cancer diagnosis in 14 (64%) of patients with a sensitivity of 64% and specificity of 100%. MRI identified all the cancers, with sensibility and specificity of 100%. Moreover, in 8 (36%) of the 22 patients who developed breast cancers, the cancers were detected only by MRI, revealing a significant superiority respect to the other surveillance modalities (P<0.05).
CONCLUSIONS: MRI demonstrated to be the best imaging modality in detection of breast cancer even for lesion <1 cm. Prophylactic mastectomy is the most effective risk reduction strategy in women at high risk, contributing to the reduction of anxiety related to the condition of a carrier.

Entities:  

Keywords:  Breast cancer; magnetic resonance imaging (MRI); mammography; screening; ultrasound

Year:  2019        PMID: 31559181      PMCID: PMC6755941          DOI: 10.21037/gs.2019.04.04

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  36 in total

1.  Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.

Authors:  Francesco Sardanelli; Franca Podo; Giuliano D'Agnolo; Arduino Verdecchia; Mariano Santaquilani; Renato Musumeci; Giovanna Trecate; Siranoush Manoukian; Sandro Morassut; Clelia de Giacomi; Massimo Federico; Laura Cortesi; Stefano Corcione; Stefano Cirillo; Vincenzo Marra; Anna Cilotti; Cosimo Di Maggio; Alfonso Fausto; Lorenzo Preda; Chiara Zuiani; Alma Contegiacomo; Antonio Orlacchio; Massimo Calabrese; Lorenzo Bonomo; Ernesto Di Cesare; Maura Tonutti; Pietro Panizza; Alessandro Del Maschio
Journal:  Radiology       Date:  2007-01-23       Impact factor: 11.105

2.  Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.

Authors:  Constance D Lehman; Jeffrey D Blume; Paul Weatherall; David Thickman; Nola Hylton; Ellen Warner; Etta Pisano; Stuart J Schnitt; Constantine Gatsonis; Mitchell Schnall; Gia A DeAngelis; Paul Stomper; Eric L Rosen; Michael O'Loughlin; Steven Harms; David A Bluemke
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

3.  First experiences in screening women at high risk for breast cancer with MR imaging.

Authors:  M M Tilanus-Linthorst; I M Obdeijn; K C Bartels; H J de Koning; M Oudkerk
Journal:  Breast Cancer Res Treat       Date:  2000-09       Impact factor: 4.872

Review 4.  Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?

Authors:  Francesco Sardanelli; Franca Podo
Journal:  Eur Radiol       Date:  2006-09-29       Impact factor: 5.315

5.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results.

Authors:  C K Kuhl; R K Schmutzler; C C Leutner; A Kempe; E Wardelmann; A Hocke; M Maringa; U Pfeifer; D Krebs; H H Schild
Journal:  Radiology       Date:  2000-04       Impact factor: 11.105

6.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Authors:  Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

7.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

8.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Authors:  Ellen Warner; Donald B Plewes; Kimberley A Hill; Petrina A Causer; Judit T Zubovits; Roberta A Jong; Margaret R Cutrara; Gerrit DeBoer; Martin J Yaffe; Sandra J Messner; Wendy S Meschino; Cameron A Piron; Steven A Narod
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

9.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

10.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  2 in total

1.  Downregulation of microRNA-30c-5p was responsible for cell migration and tumor metastasis via COTL1-mediated microfilament arrangement in breast cancer.

Authors:  Bei Pei; Tongyang Li; Qi Qian; Wenqiang Fan; Xiao He; Yulan Zhu; Lingyun Xu
Journal:  Gland Surg       Date:  2020-06

2.  Preparing PAMAM-NK4 nano complexes and examining their in vitro growth suppression effects in breast cancer.

Authors:  Minfeng Liu; Zhaoze Guo; Jiangqin Liu; Hui Ren; Jingyun Guo; Shijun Liao; Zicheng Zhang
Journal:  Gland Surg       Date:  2021-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.